Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4968770 | 1.00 | GMNN (0.30) | GMNNUSP2CYP1A2POLBCYP3A4 | |
| SCHEMBL4245758 | 0.82 | — | — | |
| SCHEMBL4245756 | 0.82 | — | — | |
| SCHEMBL11063133 | 0.80 | FDPS (0.33) | GMNNUSP2CYP1A2POLBCYP3A4 | |
| SCHEMBL11063178 | 0.80 | FDPS (0.33) | GMNNUSP2CYP1A2POLBCYP3A4 | |
| SCHEMBL6810644 | 0.78 | — | — | |
| SCHEMBL6810647 | 0.78 | — | — | |
| SCHEMBL7773897 | 0.76 | — | — | |
| SCHEMBL7773893 | 0.76 | — | — | |
| SCHEMBL725620 | 0.75 | TSHR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034015-B2 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2006-04-25 | — | — | US | claimed |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2003-06-26 | — | — | US | claimed |
| US-20080261975-A1 | Tec Kinase Inhibitors | BENTZIEN JOERG MARTIN | 2008-10-23 | — | — | US | disclosed |
| EP-1957491-A2 | PYRROLO (2,3-B) PYRIDINE DERIVATIVES USEFUL AS TEC KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007058832-A2 | PYRROLO (2, 3-B) PYRIDINE DERIVATIVES USEFUL AS TEC KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-24 | — | — | WO | disclosed |
| US-7034015-B2 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2006-04-25 | — | — | US | disclosed |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261975-A1 | Tec Kinase Inhibitors | TEC, ITK, LCK | GMNN 4359/4885USP2 4282/4885CYP1A2 2887/4885 |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | IL1B, IL1A, TNF | GMNN 4212/4885USP2 2295/4885CYP1A2 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.